<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03970447</url>
  </required_header>
  <id_info>
    <org_study_id>GCAR-7213</org_study_id>
    <nct_id>NCT03970447</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma</brief_title>
  <acronym>GBM AGILE</acronym>
  <official_title>GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Coalition for Adaptive Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Global Coalition for Adaptive Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an
      international, seamless Phase II/III response adaptive randomization platform trial designed
      to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an
      international, seamless Phase II/III response adaptive randomization platform trial designed
      to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. Its goals are to
      identify effective therapies for glioblastoma and match effective therapies with patient
      subtypes. Bayesian response adaptive randomization is used within subtypes of the disease to
      assign participants to Arms based on their performance. The primary endpoint is overall
      survival (OS).

      GBM AGILE is designed to efficiently evaluate therapies. The trial will be conducted under a
      single Master Investigational New Drug Application/Clinical Trial Application and Master
      Protocol, allowing multiple drugs and drug combinations from different pharmaceutical
      companies to be evaluated simultaneously. The plan is to add experimental therapies as new
      information about promising new drugs are identified and remove therapies as they complete
      their evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>GBM AGILE is a multi-arm, platform trial. The evaluation of each therapy in GBM AGILE proceeds in 2 possible stages. A therapy's Stage 1 is an adaptively randomized Screening stage for evaluating the therapy within patient signatures compared against a common control. A therapy in Stage 1 will stop accruing patients if it reaches its maximal sample size, drops for futility, or evinces inadequate safety. If a therapy reaches an efficacy threshold for graduation from Stage 1, it will move into Stage 2 within one of the prospectively defined signatures. The maximum sample size in Stage 1 is 150 patients.
For a therapy graduating to Stage 2 there is a fixed randomization, expansion cohort. The maximum sample size in Stage 2 is 50 experimental patients in the graduating signature. The primary analysis of a regimen's effect on OS uses all patients in both its stages and all control patients in the trial in the graduating signature, suitably adjusted for any possible time trends.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From date of randomization until the date of death from any cause, or until 12 months following last patient randomization (approximately 2 years), whichever comes first.</time_frame>
    <description>Overall survival is defined from the time of randomization to death from any cause. Patients still alive at the time of an analysis will be considered censored at their date of last contact.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From date of randomization to date of clinically determined progression or date of death from any cause, or until 12 months following last patient randomization (approximately 2 years), whichever comes first.</time_frame>
    <description>Progression-free survival is defined as the time from randomization to clinically determined progression or death from any cause. All participants will be included in the analysis of PFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>From initiation of study treatment to date of disease progression, or until 12 months following last patient randomization (approximately 2 years), whichever comes first.</time_frame>
    <description>Tumor response is categorized by Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progressive Disease (PD). Response captured from initiation of study treatment until disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (CR + PR)</measure>
    <time_frame>From date of response to date of clinically determined disease progression or date of death from any cause, or until 12 months following last patient randomization (approximately 2 years), whichever comes first.</time_frame>
    <description>Duration of response (CR+PR) is defined as time from date of response to date of clinically determined disease progression or death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Newly Diagnosed GBM: Radiation therapy (XRT) 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 2-6 weeks from the last day of radiation, and the start of the first cycle of Maintenance Therapy 2-6 weeks after the last day of radiotherapy. The start of all subsequent maintenance therapy cycles (2-12) every 4 weeks + 7 days after the first daily dose of temozolomide of the preceding cycle. Total number of cycles should comply with institutional or country standards. During maintenance therapy, the first cycle of temozolomide will be at 150 mg/m2 for Days 1-5 of a 28-day cycle. Second and subsequent cycles of maintenance therapy will be at 200 mg/m2 for Days 1-5 of a 28-day cycle.
Recurrent GBM: Lomustine started at 110 mg/m2/day on Day 1 of a 42-day cycle as per local standards. Treatment will continue for up to 6 total cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regorafenib Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Newly Diagnosed GBM: XRT 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 4 weeks from the last day of radiation. Maintenance period: Regorafenib (Dosage Form: Tablet for oral administration; Strength: 40 mg) 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).
Recurrent GBM: Regorafenib (Dosage Form: Tablet for oral administration; Strength: 40 mg) 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Dosage Form: Capsule for oral administration Strengths: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, or 250 mg</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Temodar</other_name>
    <other_name>Temodal</other_name>
    <other_name>Temcad</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lomustine</intervention_name>
    <description>Dosage Form: Capsule for oral administration Strength: 5 mg, 10 mg, 40 mg, and 100 mg</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>CCNU</other_name>
    <other_name>CeeNU</other_name>
    <other_name>Gleostine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>Dosage Form: Tablet for oral administration Strength: 40 mg Standard Regimen: 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)</description>
    <arm_group_label>Regorafenib Treatment Arm</arm_group_label>
    <other_name>Stivarga</other_name>
    <other_name>BAY 73-4506</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>60 Gy</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Regorafenib Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Newly Diagnosed Inclusion Criteria:

          -  Age ≥ 18 years.

          -  Histologically confirmed Grade IV GBM/gliosarcoma established following either a
             surgical resection or biopsy.

          -  Karnofsky performance status ≥ 60% performed within a 14-day window prior to
             randomization.

          -  Availability of tumor tissue representative of GBM from definitive surgery or biopsy.

        Recurrent Inclusion Criteria:

          -  Age ≥ 18 years.

          -  Histologically confirmed GBM/gliosarcoma (WHO criteria; non-IDH R132H mutant) at first
             or second recurrence after initial standard, control or experimental therapy that
             includes at a minimum Radiation Therapy (RT).

          -  Evidence of recurrent disease (RD) demonstrated by disease progression using slightly
             modified Response Assessment in Neuro-Oncology (RANO) criteria.

          -  Karnofsky performance status ≥ 70% performed within a 14-day window prior to
             randomization.

          -  Availability of tumor tissue representative of GBM from initial definitive surgery
             and/or, recurrent surgery, if performed.

        Newly Diagnosed Exclusion Criteria:

          -  Any prior treatment for glioma including: prior prolifeprospan 20 with carmustine
             wafer; prior intracerebral agent; prior radiation treatment for GBM or lower-grade
             glioma; prior chemotherapy or immunotherapy for GBM or lower-grade glioma.

          -  Receiving additional, concurrent, active therapy for GBM outside of the trial

          -  Extensive leptomeningeal disease.

          -  QTc &gt; 450 msec if male and QTc &gt; 470 msec if female.

          -  History of another malignancy in the previous 3 years, with a disease-free interval of
             &lt; 3 years. Patients with prior history of in situ cancer or basal or squamous cell
             skin cancer are eligible.

        Recurrent Exclusion Criteria:

          -  Early disease progression prior to 3 months (12 weeks) from the completion of RT.

          -  More than 2 prior lines for chemotherapy administration. (NOTE: In the 1st line
             adjuvant setting, combination of Temozolomide (TMZ) with an experimental agent, is
             considered one line of chemotherapy.)

          -  Any prior treatment with bevacizumab or other VEG)- or VEGF receptor-mediated targeted
             agent.

          -  Any prior treatment with prolifeprospan 20 with carmustine wafer.

          -  Any prior treatment with an intracerebral agent.

          -  Receiving additional, concurrent, active therapy for GBM outside of the trial

          -  Extensive leptomeningeal disease.

          -  QTc &gt; 450 msec if male and QTc &gt; 470 msec if female.

          -  History of another malignancy in the previous 2 years, with a disease-free interval of
             &lt; 2 years. Participant with prior history of in situ cancer or basal or squamous cell
             skin cancer are eligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Cloughesy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GCAR CMO and GBM AGILE Global PI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patient Information</last_name>
    <phone>310-598-3199</phone>
    <email>patientinfo@gcaresearch.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachel Rosenstein-Sisson</last_name>
    <email>RRosenstein.Sisson@GCAResearch.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thirumaine Pillay</last_name>
      <phone>205-934-1824</phone>
      <email>tpillay@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Louis B Nabors, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Lichti</last_name>
      <phone>714-714-6220</phone>
      <email>Christine.lichti@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>Lars Anker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Compton</last_name>
      <phone>720-848-8312</phone>
      <email>Julie.Compton@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Denise Damek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center / Smilow Cancer Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Fleischmann</last_name>
      <phone>203-737-5645</phone>
      <email>Kristin.Fleischmann@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Nicholas Blondin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Liendo</last_name>
      <email>mliendo@med.miami.edu</email>
    </contact>
    <contact_backup>
      <phone>305-243-0864</phone>
    </contact_backup>
    <investigator>
      <last_name>Macarena I De La Fuente, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yazmin Rodriguez</last_name>
      <phone>813-745-3353</phone>
      <email>Yazmin.rodriguez@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Peter Forsyth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Atlanta Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Arabnia</last_name>
      <phone>404-425-7943</phone>
      <email>Ali.arabnia@piedmont.org</email>
    </contact>
    <contact_backup>
      <last_name>Dionne Jean</last_name>
      <phone>404-425-7927</phone>
      <email>dionne.jean@Piedmont.org</email>
    </contact_backup>
    <investigator>
      <last_name>Erin Dunbar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Racquel Williams</last_name>
      <phone>404-778-7354</phone>
      <email>rwill41@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Olson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LSU Health Sciences Center - New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Fannin</last_name>
      <phone>504-568-2641</phone>
      <email>efanni@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Aaron Mammoser, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Pearce</last_name>
      <phone>313-575-8046</phone>
      <email>Tpearce1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Tommy Mikkelsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Ellenberger</last_name>
      <phone>612-863-6562</phone>
      <email>Amy.Ellenberger@allina.com</email>
    </contact>
    <investigator>
      <last_name>John E Trusheim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Barnes</last_name>
      <phone>601-815-4540</phone>
      <email>jbarnes@umc.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine - Siteman Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Puspanjali Bhatta</last_name>
      <phone>314-286-0896</phone>
      <email>pbhatta@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Grayson Talcott</last_name>
      <phone>314-273-0656</phone>
      <email>wu-grayson@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jian Campian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Stangarone</last_name>
      <phone>212-241-9843</phone>
      <email>angela.stangarone@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Lyndon Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Olmos</last_name>
      <phone>212-342-5162</phone>
      <email>cancerclinicaltrials@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Lassman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Burleigh, MS</last_name>
      <phone>212-610-0261</phone>
      <email>burleiga@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Ingo Mellinghoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Murphy, RN</last_name>
      <phone>216-983-3021</phone>
      <email>mailto:Christopher.Murphy@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Robin Buerki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania - Perelman Center for Advanced Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Fernandez</last_name>
      <phone>267-474-3211</phone>
      <email>Peter.Fernandez@Pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Arati Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Stoker</last_name>
      <phone>412-330-6106</phone>
      <email>Elizabeth.stoker@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Tulika Ranjan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center - Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Winkelman</last_name>
      <phone>412-647-7393</phone>
      <email>winkelmanm@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jan Drappatz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina - Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Keller</last_name>
      <phone>843-792-2209</phone>
      <email>Kellej@musc.edu</email>
    </contact>
    <investigator>
      <last_name>David Cachia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Brueggemann</last_name>
      <phone>512-421-4108</phone>
      <email>Kristen.Brueggemann@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Andrew Brenner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simic Zorica</last_name>
      <phone>214-648-5221</phone>
      <email>Zorica.Simic@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Edward Pan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Alfaro</last_name>
      <phone>713-792-1281</phone>
      <email>KDAlfaro@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>John de Groot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah - Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brett Johnson</last_name>
      <phone>801-587-4429</phone>
      <email>Brett.Johnson@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Howard Colman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CJ Woodburn</last_name>
      <phone>434-243-9900</phone>
      <email>cjw4v@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>David Schiff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie A Hogl</last_name>
      <phone>206-616-8767</phone>
      <email>lalnaser@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Jerome Graber, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital/Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Lasowski</last_name>
      <phone>414-805-8375</phone>
      <email>mlasowski@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Connelly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>Newly diagnosed</keyword>
  <keyword>recurrent</keyword>
  <keyword>O6-methylguanine-DNA-methyltransferase (MGMT) methylated</keyword>
  <keyword>MGMT unmethylated</keyword>
  <keyword>isocitrate dehydrogenase (IDH) wild-type</keyword>
  <keyword>Bayesian</keyword>
  <keyword>adaptive randomization</keyword>
  <keyword>Master Protocol</keyword>
  <keyword>Platform Trial</keyword>
  <keyword>Phase 2</keyword>
  <keyword>Phase 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Lomustine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Global Coalition for Adaptive Research (GCAR) is in the planning stages at this time.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

